To address if the MLD strategy is effective in vivo, we used patient derived xenograft (PDX) tumours from four different patients who had developed resistance to first-line or second-line therapy with EGFR inhibitors erlotinib or osimertinib22 in the clinic by acquiring EGFR T790M mutation, KRAS mutation or MET amplification (Supplementary Table 3). Here, KRAS is linked to neoplasm.